pancreatic ductal adenocarcinoma

[Gastroenterology] Investigators discuss the pathogenesis of PDAC, including molecular alterations in tumor cells, cellular alterations in the tumor microenvironment, and population-level risk factors.

[Journal of Pathology] Investigators determined if patient-derived organoids (PDOs) could be used to personalize poly-chemotherapy regimens by pharmacotyping of treatment-naïve and post neoadjuvant chemotherapy PDAC PDOs.

[Nature Communications] Investigators systematically dissected pancreatic ductal adenocarcinoma intrinsic mechanisms of immune evasion by in vitro and in vivo CRISPR screening, and identified Vps4b and Rnf31 as essential factors required for escaping CD8+ T cell killing.

[Microsystems & Nanoengineering] The authors developed a tumor-chip device engineered to mimic the pancreatic ductal adenocarcinoma tumor microenvironment by incorporating patient-derived organoids and stromal cells, specifically pancreatic stellate cells and macrophages.

[Cell Death & Disease] Researchers observed that trefoil factor 3 (TFF3) expression was elevated in PDAC, and was positively correlated with a worse overall patient survival outcome.

[Acta Pharmacologica Sinica] Two pan-KRAS inhibitors, BI-2852 and BAY-293, were chosen as chemical probes to investigate their antitumor potency in PDAC.